FluoroPharma Medical IncOver The Counter Market:FPMI
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
FluoroPharma Medical Inc | 3.4K | 0.0x | --- |
ARYx Therapeutics Inc | 30.0 | 0.0x | --- |
PZ Wind Down Inc | 2.3K | 0.0x | --- |
Allon Therapeutics Inc | 14.1K | 0.0x | --- |
Rebus Holdings Inc | 3.2K | 0.0x | --- |
Verde Science Inc | 20.0 | 0.0x | --- |
Company Information
FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The Company is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). BFPET program employs a (18F)-labeled cationic lipophilic tetraphenylphosphonium ion as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. It measures the extent and severity of cardiovascular disease through the detection of ischemic and infarcted myocardial tissue. CardioPET program employs Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
Contact Information
- Headquarters
- 8 Hillside Ave Ste 207MONTCLAIR, NJ, United States 07042-2129
- Phone
- 973-744-1565
- Fax
- 617-482-3337
Executives
- Independent interim chairman of the board
- Walter Witoshkin
- President, Treasurer, Company Secretary
- Ambrose Egbuonu
- Chief Executive Officer, Director
- Thomas Tulip
- Chief Financial Officer, Controller, Director
- Frank Igwealor
- Independent Director
- William Lewis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.08 |
Book Value | $-0.30 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
